Abbvie Inc
NYSE: ABBV
$166.28
+$1.29 (+0.8%)
Closing Price on November 18, 2024
ABBV Articles
We screened the Jefferies Franchise Pick List for top stocks rated Buy with the highest upside to the Jefferies price targets.
Published:
The May 29 short interest data have been compared with the previous figures, and for most of the selected pharmaceutical stocks, short interest is down.
Published:
AT&T continued to reign as the most shorted stock trading on the New York Stock Exchange between the May 15 and May 29 settlement dates.
Published:
Credit Suisse has updated its autoimmune market model and it sees implications for all of the large cap U.S. pharmaceutical companies in its coverage.
Published:
Halozyme Therapeutics has announced a global collaboration and license agreement with AbbVie.
Published:
ThinkstockThe American Society of Clinical Oncology’s (ASCO) annual meeting is coming to a close. Companies and cancer drug developers across the health care sector flock to this conference to...
Published:
The short interest data has been released for the May 15 settlement date and for the selected pharmaceutical stocks, short interest is mixed.
Published:
Wednesday's top analyst upgrades, downgrades and initiations include Ambarella, eBay, Rite Aid, TiVo, Yahoo, Valero Energy and Virtu Financial.
Published:
With major mergers and acquisition deals happening, and a host of clinical trials that could offer some outstanding breakthrough drug treatments, the big pharmaceutical stocks have had their fair...
Published:
The April 30 short interest data have been compared with the previous figures, and for the selected pharmaceutical stocks, short interest is mixed.
Published:
In a new report, Deutsche Bank acknowledges that while the industry has shown recent weakness, now may be just the right time to add biotech stocks.
Published:
Credit Suisse has released a report that detailed its top picks for pharmaceutical stocks for the rest of 2015.
Published:
A new report from Deutsche Bank highlights all of the known risks and focuses in on stocks that are reasonable in a pricey market.
Published:
Last Updated:
In a new report, Cowen analysts have sights set on three major pharmaceutical stocks that they expect to have rising first-quarter earnings.
Published:
24/7 Wall St. has found four good examples of blue-chip stocks that got a little tarnished recently for one reason or another, that investors may want to reexamine.
Published: